Molecular epidemiology of group a streptococcus from pharyngeal isolates in Auckland, New Zealand, 2013

New Zealand Medical Journal

Volumn 127, Issue 1388, 2014, Pages 55-60

  Williamson, Deborah A ^a,b,d   Moreland, Nicole J ^c   Carter, Philip ^b   Upton, Arlo ^d   Morgan, Julie ^a   Proft, Thomas ^a   Lennon, Diana ^a   Baker, Michael G ^e   Dunbar, Rod ^c   Fraser, John D ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d LabTests Pathology   (New Zealand)

^e UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIUM ISOLATE; CHILD; EMM 12; EMM 89; EMM GENE; FEMALE; GENE; GENE SEQUENCE; HEALTH; HUMAN; HUMAN TISSUE; MALE; MOLECULAR EPIDEMIOLOGY; NEW ZEALAND; NONHUMAN; PHARYNGITIS; POLYMERASE CHAIN REACTION; STREPTOCOCCUS GROUP A; THROAT CULTURE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DNA, BACTERIAL; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; NEW ZEALAND; PHARYNGITIS; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; URBAN POPULATION; YOUNG ADULT;

EID: 84893313662     PISSN: 00288446     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005;5:685-94.
2. Ralph AP, Carapetis JR. Group A streptococcal diseases and their global burden. Curr Top Microbiol Immunol 2013;368:1-27.
3. Milne RJ, Lennon D, Stewart JM, Vander Hoorn S, Scuffham PA. Mortality and hospitalisation costs of rheumatic fever and rheumatic heart disease in New Zealand. J Paediatr Child Health 2012;48:692-7.
4. Wong W, Lennon DR, Crone S, Neutze JM, Reed PW. Prospective population-based study on the burden of disease from post-streptococcal glomerulonephritis of hospitalised children in New Zealand: Epidemiology, clinical features and complications. J Paediatr Child Health 2013 [Jun 18th, Epub ahead of print].
5. Jaine R, Baker M, Venugopal K. Epidemiology of acute rheumatic fever in New Zealand 1996-2005. J Paediatr Child Health 2008;44:564-71.
6. Milne RJ, Lennon DR, Stewart JM, Vander Hoorn S, Scuffham PA. Incidence of acute rheumatic fever in New Zealand children and youth. J Paediatr Child Health 2012;48:685-91.
7. Jaine R, Baker M, Venugopal K. Acute rheumatic fever associated with household crowding in a developed country. Pediatr Infect Dis J 2011;30:315-9.
8. New Zealand Ministry of Health. Rheumatic fever prevention programme (http://www.health.govt.nz/our-work/diseases-and-conditions/rheumatic-fever, last accessed 26th July 2013).
9. Gray S, Lennon D, Anderson P, Stewart J, Farrell E. Nurse-led school-based clinics for rheumatic fever and skin infections: Results from a pilot study in south Auckland. N Z Med J 2013;126:53-61.
10. Dale JB, Fischetti VA, Carapetis JR, et al. Group A streptococcal vaccines: Paving a path for accelerated development. Vaccine 2013;31 Suppl 2:B216-22.
11. Good MF, Batzloff MR, Pandey M. Strategies in the development of vaccines to prevent infections with group A streptococcus. Hum Vaccin Immunother 2013;9(11).
12. Guilherme L, Ferreira FM, Kohler KF, Postol E, Kalil J. A vaccine against Streptococcus pyogenes: The potential to prevent rheumatic fever and rheumatic heart disease. Am J Cardiovasc Drugs 2013;13:1-4.
13. Bensi G, Mora M, Tuscano G, et al. Multi high-throughput approach for highly selective identification of vaccine candidates: The group A streptococcus case. Mol Cell Proteomics 2012 11:M111.015693.
14. McNeil SA, Halperin SA, Langley JM, et al. Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005;41:1114-22.
15. Beall B, Facklam R, Thompson T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol 1996;34:953-8.
16. Grundmann H, Hori S, Tanner G. Determining confidence intervals when measuring genetic diversity and the discriminatory abilities of typing methods for microorganisms. J Clin Microbiol 2001;39:4190-2.
17. Dale JB, Penfound TA, Chiang EY, Walton WJ. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine 2011;29:8175-8.
18. Dale JB, Penfound TA, Tamboura B, et al. Potential coverage of a multivalent M proteinbased group A streptococcal vaccine. Vaccine 2013;31:1576-81.
19. Shulman ST, Tanz RR, Dale JB, et al. Seven-year surveillance of North American pediatric group A streptococcal pharyngitis isolates. Clin Infect Dis 2009;49:78-84.
20. Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR. Global emm type distribution of group A streptococci: Systematic review and implications for vaccine development. Lancet Infect Dis 2009;9:611-6.
21. Shea PR, Ewbank AL, Gonzalez-Lugo JH, et al. Group A streptococcus emm gene types in pharyngeal isolates, Ontario, Canada, 2002-2010. Emerg Infect Dis 2011;17:2010-7.
22. Safar A, Lennon D, Stewart J, et al. Invasive group A streptococcal infection and vaccine implications, Auckland, New Zealand. Emerg Infect Dis 2011;17:983-9.